Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Clovis Oncology stock

C6O.F
US1894641000
A1JPJY

Price

0.02
Today +/-
+0
Today %
+0 %

Clovis Oncology stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Clovis Oncology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Clovis Oncology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Clovis Oncology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Clovis Oncology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Clovis Oncology Stock Price History

DateClovis Oncology Price
7/17/20230.02 undefined
7/14/20230.03 undefined

Clovis Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Clovis Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Clovis Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Clovis Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Clovis Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Clovis Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Clovis Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Clovis Oncology’s growth potential.

Clovis Oncology Revenue, EBIT and net profit per share

DateClovis Oncology RevenueClovis Oncology EBITClovis Oncology Net Income
2024e173.72 M undefined-98.39 M undefined-70.18 M undefined
2023e160.36 M undefined-143.83 M undefined-117.21 M undefined
2022e133.09 M undefined-201.28 M undefined-240.39 M undefined
2021148.76 M undefined-220.29 M undefined-264.52 M undefined
2020164.52 M undefined-302.19 M undefined-369.21 M undefined
2019143.01 M undefined-367.31 M undefined-400.42 M undefined

Clovis Oncology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2019202020212022e2023e2024e
143164148133160173
-14.69-9.76-10.1420.308.13
75.5275.0073.6581.9568.1363.01
108123109000
-400-369-264-240-117-70
--7.75-28.46-9.09-51.25-40.17
53.8784.31115.53000
------
Details

Keystats

ⓘ

Revenue and Growth

The Clovis Oncology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Clovis Oncology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201920202021
     
296.66240.23143.43
20.5626.5126.87
14.14.096.81
26.5230.7113.69
8.639.297.3
366.47310.83198.09
43.4342.5225.66
000
000
62.9265.7460.37
63.0763.0763.07
133.71123.39125.64
303.14294.72274.75
669.6605.55472.83
     
55104129
2.112.52.64
-2,243.52-2,612.73-2,877.25
-44.73-44.17-43.29
-0.13-0.14-0.14
-174.26-158.75-278.84
32.2426.6927.31
97.3493.1387.83
3.510.911.58
000
064.28.5
133.08184.93125.21
679.74545.76606.73
000
31.0433.6119.73
710.78579.37626.46
843.86764.3751.67
669.6605.55472.83
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Clovis Oncology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Clovis Oncology's financial health and stability.

Assets

Clovis Oncology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Clovis Oncology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Clovis Oncology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Clovis Oncology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201920202021
-400-369-264
788
000
81130
609629
101211
000
-323-252-196
-19-80
1431260
1621340
000
116-44-17
3248118
119203100
---
000
-6078-96
-342.66-261.08-196.37
000

Clovis Oncology stock margins

The Clovis Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Clovis Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Clovis Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Clovis Oncology's sales revenue. A higher gross margin percentage indicates that the Clovis Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Clovis Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Clovis Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Clovis Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Clovis Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Clovis Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Clovis Oncology Margin History

Clovis Oncology Gross marginClovis Oncology Profit marginClovis Oncology EBIT marginClovis Oncology Profit margin
2024e73.9 %-56.64 %-40.4 %
2023e73.9 %-89.69 %-73.09 %
2022e73.9 %-151.24 %-180.62 %
202173.9 %-148.09 %-177.82 %
202074.89 %-183.68 %-224.41 %
201975.75 %-256.85 %-280.01 %

Clovis Oncology Stock Sales Revenue, EBIT, Earnings per Share

The Clovis Oncology earnings per share therefore indicates how much revenue Clovis Oncology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clovis Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clovis Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clovis Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clovis Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Clovis Oncology Revenue, EBIT and net profit per share

DateClovis Oncology Sales per ShareClovis Oncology EBIT per shareClovis Oncology Earnings per Share
2024e1.2 undefined0 undefined-0.48 undefined
2023e1.11 undefined0 undefined-0.81 undefined
2022e0.92 undefined0 undefined-1.66 undefined
20211.29 undefined-1.91 undefined-2.29 undefined
20201.95 undefined-3.58 undefined-4.38 undefined
20192.65 undefined-6.82 undefined-7.43 undefined

Clovis Oncology business model

Clovis Oncology Inc. is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. The company is based in Boulder, Colorado and was founded in 2009. They focus on researching and developing innovative therapies for cancer patients. History: Clovis Oncology was founded by Patrick Mahaffy and his team, who previously worked at Pharmion Corporation and sold the biotech company to Celgene. After the sale of Pharmion, Mahaffy and his colleagues wanted to build something new and started Clovis Oncology. Clovis started its activities in 2009 and initially focused on the development of PARP inhibitors, which can be used for the treatment of breast and ovarian cancer. In 2011, the company conducted Phase I studies with its leading product candidate, Rucaparib. Business model: Clovis Oncology has a business model based on the discovery, development, and commercialization of innovative cancer therapies. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a global network of research and development facilities that allows them to focus on the therapy areas where they are best positioned. Through partnerships and licenses, the company also has access to specialized technologies and expertise in cancer research. Divisions: Clovis Oncology is divided into two divisions: 1. Research and development: Clovis operates an intensive research and development program focused on the discovery and development of new cancer therapies. The focus is on developing PARP inhibitors that offer new treatments for breast and ovarian cancer. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a strong pipeline of products in various stages of clinical development. 2. Commercialization: Clovis also has an experienced marketing team responsible for the marketing and distribution of Rucaparib. Rucaparib is a PARP inhibitor approved for the treatment of breast and ovarian cancer in the United States and several other countries. Products: The main product of Clovis Oncology is Rucaparib, a PARP inhibitor for the treatment of breast and ovarian cancer. The medication was approved by the US Food and Drug Administration (FDA) in December 2016 for use in patients with advanced ovarian cancer. Clovis also has a pipeline of products in various stages of clinical development. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Summary: Clovis Oncology is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. They have a focus on developing PARP inhibitors and currently offer Rucaparib for the treatment of breast and ovarian cancer. Clovis has a strong pipeline of products in various stages of clinical development and collaborates closely with academic institutions and other companies to advance cancer research. Clovis Oncology is one of the most popular companies on Eulerpool.com.

Clovis Oncology SWOT Analysis

Strengths

1. Solid Product Portfolio: Clovis Oncology Inc has a diverse range of innovative oncology drugs and treatments.

2. Strong Research and Development: The company invests significantly in R&D, allowing it to stay at the forefront of advancements in cancer treatment.

3. Established Market Presence: Clovis Oncology has built a strong reputation and brand recognition in the oncology industry.

Weaknesses

1. Financial Dependence: The company relies heavily on funding from investors and partners to support its research and development activities.

2. Limited Product Pipeline: Clovis Oncology has a relatively small pipeline of drugs, which increases its vulnerability to market fluctuations and competition.

3. High Research Costs: Developing and testing new drugs is expensive, and this puts significant financial strain on the company.

Opportunities

1. Growing Demand for Cancer Treatments: With the increasing prevalence of cancer worldwide, there is a significant opportunity for Clovis Oncology to expand its market share.

2. Strategic Partnerships: Collaborating with other pharmaceutical companies or research institutions can provide access to new technologies, resources, and markets.

3. Emerging Markets: Clovis Oncology can explore untapped markets in developing countries where the demand for quality cancer treatments is growing.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for the same market share.

2. Regulatory Challenges: The stringent regulatory requirements for drug approval, safety, and efficacy pose challenges and delays in bringing new drugs to market.

3. Pricing Pressures: Governments, insurance companies, and healthcare systems exert pressure on drug pricing, potentially impacting the profitability of Clovis Oncology.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Clovis Oncology Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Clovis Oncology historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Clovis Oncology shares outstanding

The number of shares was Clovis Oncology in 2024 — This indicates how many shares 115.528 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clovis Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clovis Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clovis Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clovis Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Clovis Oncology.

Clovis Oncology latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-0.43 -0.39  (8.39 %)2022 Q3
6/30/2022-0.43 -0.5  (-17.45 %)2022 Q2
3/31/2022-0.45 -0.44  (1.23 %)2022 Q1
12/31/2021-0.59 -0.48  (18.24 %)2021 Q4
9/30/2021-0.49 -0.56  (-13.75 %)2021 Q3
6/30/2021-0.58 -0.61  (-4.81 %)2021 Q2
3/31/2021-0.74 -0.64  (13.5 %)2021 Q1
12/31/2020-0.79 -1.02  (-28.61 %)2020 Q4
9/30/2020-1.02 -0.89  (12.86 %)2020 Q3
6/30/2020-1.08 -1.15  (-6.9 %)2020 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Clovis Oncology stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

66

👫 Social

48

🏛️ Governance

64

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Clovis Oncology shareholders

%
Name
Stocks
Change
Date
0.66969 % Mahaffy (Patrick J)970,78704/11/2022
0.44966 % Aberdare Ventures651,83312,7554/11/2022
0.34492 % Healthcare Value Capital, LLC500,00009/30/2021
0.27683 % AXA Rosenberg Investment Management LLC401,300401,30012/31/2021
0.20255 % Ivers-Read (Gillian C)293,6124,69311/2/2022
0.18489 % McKinley (Edward J)268,01604/11/2022
0.17260 % Macquarie Investment Management250,200012/31/2022
0.07843 % Rolfe (Lindsey)113,6914,11311/2/2022
0.07588 % Signal Iduna Asset Management GmbH110,00061,00012/31/2022
0.07232 % Muehl (Daniel W)104,8305,66911/2/2022
1
2
3
4
5
...
10

Clovis Oncology Executives and Management Board

Mr. Patrick Mahaffy

(59)
Clovis Oncology President, Chief Executive Officer, Co-Founder, Director (since 2009)
Compensation 2.64 M

Dr. Lindsey Rolfe

(54)
Clovis Oncology Executive Vice President - Clinical Development and Pharmacovigilance and Chief Medical Officer
Compensation 1.24 M

Ms. Gillian Ivers - Read

(68)
Clovis Oncology Co-Founder, Executive Vice President, Chief Regulatory Officer
Compensation 1.21 M

Mr. Paul Gross

(57)
Clovis Oncology Executive Vice President, General Counsel
Compensation 1.2 M

Mr. Daniel Muehl

(59)
Clovis Oncology Chief Financial Officer, Executive Vice President
Compensation 1.19 M
1
2
3
4

Most common questions regarding Clovis Oncology

What values and corporate philosophy does Clovis Oncology represent?

Clovis Oncology Inc is a renowned biopharmaceutical company specializing in innovative cancer treatments. With a strong commitment to improving patient outcomes, Clovis Oncology upholds values of scientific excellence, integrity, and compassion. The company's corporate philosophy centers around pioneering research, developing targeted therapies, and collaborating with healthcare professionals to advance cancer care. Clovis Oncology prioritizes patient-centricity, aiming to address unmet medical needs and provide hope for individuals affected by cancer. Through its dedication to scientific advancements and ethical practices, Clovis Oncology remains at the forefront of oncology research, striving to make a positive impact on the lives of cancer patients worldwide.

In which countries and regions is Clovis Oncology primarily present?

Clovis Oncology Inc is primarily present in the United States and Europe. With headquarters in Boulder, Colorado, the company operates throughout the United States, serving patients with oncology-focused therapies. Additionally, Clovis Oncology has a significant presence in Europe, particularly in countries such as Germany, France, Italy, Spain, and the United Kingdom. By catering to both American and European markets, the company aims to provide its innovative oncology solutions to a wide range of patients and healthcare professionals in these regions.

What significant milestones has the company Clovis Oncology achieved?

Clovis Oncology Inc has achieved several significant milestones in its journey. One notable achievement is the FDA approval of its PARP inhibitor, Rubraca (rucaparib), for the treatment of advanced ovarian cancer in patients with BRCA mutations. This milestone demonstrated the company's commitment to developing innovative therapies for cancer patients. Additionally, Clovis Oncology Inc successfully completed the ARIEL3 clinical trial, showcasing the efficacy and safety of Rubraca in recurrent ovarian cancer patients. The company's efforts in expanding Rubraca's indications and exploring new treatment possibilities highlight its dedication to improving patient outcomes in the oncology field.

What is the history and background of the company Clovis Oncology?

Clovis Oncology Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative cancer treatments. Founded in 2009, Clovis Oncology has quickly emerged as a prominent player in the field, committed to providing novel therapies for patients with difficult-to-treat cancers. The company's focus lies in developing precision medicines that target specific genetic mutations, enabling personalized cancer treatment options. With a strong pipeline of investigational drugs and collaborations with leading research institutions, Clovis Oncology strives to revolutionize cancer care and improve patient outcomes. Clovis Oncology Inc has established itself as a trusted name in the oncology sector, dedicated to addressing unmet medical needs and fostering hope in the fight against cancer.

Who are the main competitors of Clovis Oncology in the market?

The main competitors of Clovis Oncology Inc in the market include other pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, and Pfizer. These companies also focus on developing and commercializing oncology treatments and therapies. However, Clovis Oncology Inc stands out in the market with its innovative approach and a strong pipeline of cancer drugs, including Rubraca (rucaparib) for the treatment of ovarian cancer.

In which industries is Clovis Oncology primarily active?

Clovis Oncology Inc is primarily active in the pharmaceutical industry, specifically in the field of oncology. The company focuses on developing innovative cancer treatments and therapies. With a dedicated team of professionals and cutting-edge research, Clovis Oncology Inc aims to improve the lives of cancer patients worldwide. Their commitment to oncology reflects in their broad portfolio of targeted therapies and clinical pipeline. Clovis Oncology Inc's continuous efforts in advancing cancer treatments have positioned them as a key player in the pharmaceutical industry, making them a promising investment option for those interested in the oncology sector.

What is the business model of Clovis Oncology?

Clovis Oncology Inc operates as a biopharmaceutical company focused on developing and commercializing innovative cancer treatments. The business model of Clovis Oncology revolves around the research, development, and commercialization of targeted therapies for individuals with specific types of cancer. By leveraging their expertise in precision medicine, the company aims to identify and address unmet medical needs in the oncology field. Clovis Oncology is committed to advancing their pipeline of investigational drug candidates and collaborating with key stakeholders to improve patient outcomes and quality of life.

What is the P/E ratio of Clovis Oncology 2025?

The P/E ratio cannot be calculated for Clovis Oncology at the moment.

What is the P/S ratio of Clovis Oncology 2025?

The P/S cannot be calculated for Clovis Oncology currently.

What is the Quality Investing of Clovis Oncology?

The Quality Investing for Clovis Oncology is 2/10.

What is the revenue of Clovis Oncology 2025?

The revenue cannot currently be calculated for Clovis Oncology.

How high is the profit of Clovis Oncology 2025?

The profit cannot currently be calculated for Clovis Oncology.

What is the business model of Clovis Oncology

Clovis Oncology Inc. is a biopharmaceutical company specializing in the development and marketing of cancer therapies. It was founded in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology offers innovative therapies for the treatment of cancer patients, particularly in the areas of ovarian and lung cancer. The company invests in the discovery of new molecules and drugs to meet the specific needs of cancer patients. The three main divisions of Clovis Oncology are research and development, clinical trials, and the commercialization of cancer therapies. In research and development, the company invests in the discovery of new molecules and the development of drugs for the treatment of cancer. Clovis Oncology has a wide portfolio of drugs for the treatment of various types of cancer, including Rucaparib and Lucitanib. Clinical trials are an important part of Clovis Oncology's business model. The company continuously conducts clinical trials to evaluate the effectiveness and safety of its drugs. These studies typically involve multiple phases, starting with safety and dosage evaluation and ending with efficacy assessment and FDA approval. The commercialization of Clovis Oncology's cancer therapies is the final step in the process. Once the drug is approved by the FDA, it is introduced to the market. This is usually done through sales and distribution networks of healthcare providers to market the drug to cancer patients. Clovis Oncology also provides support programs to improve the treatment of cancer patients. Overall, Clovis Oncology's business model is focused on the research, development, and commercialization of cancer therapies. The company is committed to improving patient care and contributing to the improvement of the lives of cancer patients worldwide.

What is the Clovis Oncology dividend?

Clovis Oncology pays a dividend of 0 USD distributed over payouts per year.

How often does Clovis Oncology pay dividends?

The dividend cannot currently be calculated for Clovis Oncology or the company does not pay out a dividend.

What is the Clovis Oncology ISIN?

The ISIN of Clovis Oncology is US1894641000.

What is the Clovis Oncology WKN?

The WKN of Clovis Oncology is A1JPJY.

What is the Clovis Oncology ticker?

The ticker of Clovis Oncology is C6O.F.

How much dividend does Clovis Oncology pay?

Over the past 12 months, Clovis Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clovis Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Clovis Oncology?

The current dividend yield of Clovis Oncology is .

When does Clovis Oncology pay dividends?

Clovis Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clovis Oncology?

Clovis Oncology paid dividends every year for the past 0 years.

What is the dividend of Clovis Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clovis Oncology located?

Clovis Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clovis Oncology from 1/11/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/11/2025.

When did Clovis Oncology pay the last dividend?

The last dividend was paid out on 1/11/2025.

What was the dividend of Clovis Oncology in the year 2024?

In the year 2024, Clovis Oncology distributed 0 USD as dividends.

In which currency does Clovis Oncology pay out the dividend?

The dividends of Clovis Oncology are distributed in USD.

All fundamentals about Clovis Oncology

Our stock analysis for Clovis Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clovis Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.